ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for ESTROGEN RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ESTROGEN RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ESTROGEN RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine aims to fight breast cancer by training the immune system
⭐️ VACCINE ⭐️ OngoingThis early-phase study tests a vaccine made from estrogen receptor peptides, combined with immune boosters, in 8 people with ER-positive breast cancer who have completed standard therapy. The goal is to see if the vaccine is safe and can trigger an immune response against cancer …
Matched conditions: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Herbert Lyerly • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:08 UTC
-
Immune booster before chemo shows promise for tough breast cancer
Disease control OngoingThis study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can help the immune system attack HER2-negative breast cancer more effectively. About 46 adults with locally advanced disease will receive a short course of these d…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 02, 2026 04:00 UTC
-
Can a drug combo shrink breast tumors better before surgery?
Disease control OngoingThis phase 3 trial tests whether giving fulvestrant alone or with anastrozole before surgery works better than anastrozole alone for postmenopausal women with estrogen receptor-positive breast cancer. Over 1,400 participants will receive one of these hormone therapies for several…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo shows promise against hereditary breast cancer
Disease control OngoingThis study tests two drugs, niraparib and dostarlimab, given before surgery to people with BRCA- or PALB2-mutated breast cancer. The goal is to see if this combination boosts the immune system's attack on the tumor and leads to a complete response (no cancer left at surgery). Abo…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug cocktail aims to shrink breast tumors before surgery
Disease control OngoingThis study tests whether combining hormone therapy, a targeted drug (palbociclib), and an immunotherapy (avelumab) can shrink early-stage, hormone-positive breast tumors before surgery. About 33 women with stage II-III breast cancer will receive the treatment for about 4 months, …
Matched conditions: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug cocktail shows promise in slowing HER2-Positive breast cancer
Disease control OngoingThis phase 3 trial tests whether adding the drug palbociclib to standard anti-HER2 therapy and hormone therapy can help people with HR+/HER2+ metastatic breast cancer live longer without their cancer getting worse. About 518 participants who have already received initial treatmen…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug combo shows promise in slowing advanced breast cancer
Disease control OngoingThis study tests whether adding a targeted drug called AZD5363 to the standard hormone therapy fulvestrant can slow the growth of advanced estrogen-receptor-positive (ER+) breast cancer. It involves 149 postmenopausal women whose cancer has worsened despite prior treatment with a…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Velindre NHS Trust • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Can a Sugar-Tracking scan predict cancer treatment success?
Diagnosis OngoingThis study looks at whether a special type of PET/CT scan (called FDG PET/CT) can help doctors see how well hormone therapy is working in breast cancer that has spread to the bones. About 75 adults with estrogen receptor-positive breast cancer and bone metastases will get the sca…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
Sponsor: University of Pennsylvania • Aim: Diagnosis
Last updated Jun 26, 2026 13:12 UTC
-
Can a vaginal ring or moisturizer ease dryness for breast cancer survivors?
Symptom relief OngoingThis study looks at two treatments for vaginal dryness in women with estrogen receptor-positive breast cancer who are taking aromatase inhibitors. One group uses a vaginal estrogen ring that releases a low dose of estrogen over 90 days, while the other uses a non-hormonal vaginal…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Polly A. Niravath, MD • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Blood tests may spare breast cancer patients from unnecessary scans
Knowledge-focused OngoingThis study looks at whether simple blood tests can tell if a woman's metastatic breast cancer is stable, so she can skip some routine scans. About 97 women with ER-positive/HER2-negative cancer will give blood samples at each scan visit. The goal is to create a smart algorithm th…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
Sponsor: The Christie NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC